Vosoritide for achondroplasia

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 3 trial. Large late-stage trial in people. As of 19 Nov 2026, from 7 registered trials.

Why this status

  1. 12 Dec 2016: Trial started, NCT03197766
  2. 23 Jun 2017: Trial registered, NCT03197766
  3. 12 Dec 2017: Trial started, NCT03424018
  4. 6 Feb 2018: Trial registered, NCT03424018

The trials

NCT02055157: A Phase 2 Study of BMN 111 to Evaluate Safety, Tolerability, and Efficacy in Children With Achondroplasia

State
Completed
Phase
Phase 2
People
35 taking part
Started
13 Jan 2014
Primary completion
2 Oct 2017
Arms
Cohort 1, Cohort 2, Cohort 3, Cohort 4
Results
Posted on the registry
  1. 13 Jan 2014: Trial started
  2. 5 Feb 2014: Trial registered
  3. 2 Oct 2017: Trial completed
  4. 15 Jan 2021: Trial results posted

NCT02724228: A Study to Evaluate Long-Term Safety, Tolerability, & Efficacy of BMN 111 in Children With Achondroplasia (ACH)

State
Under way
Phase
Phase 2
People
30 taking part
Started
26 Jan 2016
Primary completion
Dec 2027
Arms
BMN 111 - Subcutaneous Injection
Results
None posted
  1. 26 Jan 2016: Trial started
  2. 31 Mar 2016: Trial registered

NCT03197766: A Study to Evaluate the Efficacy and Safety of BMN 111 in Children With Achondroplasia

State
Completed
Phase
Phase 3
People
121 taking part
Started
12 Dec 2016
Primary completion
30 Oct 2019
Arms
Active BMN 111
Results
Posted on the registry
  1. 12 Dec 2016: Trial started
  2. 23 Jun 2017: Trial registered
  3. 30 Oct 2019: Trial completed
  4. 2 Mar 2022: Trial results posted

NCT03424018: An Extension Study to Evaluate the Efficacy and Safety of BMN 111 in Children With Achondroplasia

State
Under way
Phase
Phase 3
People
119 taking part
Started
12 Dec 2017
Primary completion
Jun 2031
Arms
BMN 111
Results
None posted
  1. 12 Dec 2017: Trial started
  2. 6 Feb 2018: Trial registered

NCT03583697: A Clinical Trial to Evaluate the Safety and Efficacy of BMN 111 in Infants and Young Children With Achondroplasia

State
Completed
Phase
Phase 2
People
75 taking part
Started
13 Jun 2018
Primary completion
26 Jan 2022
Arms
Active BMN111
Results
Posted on the registry
  1. 13 Jun 2018: Trial started
  2. 11 Jul 2018: Trial registered
  3. 26 Jan 2022: Trial completed
  4. 13 Jun 2024: Trial results posted

NCT03989947: An Extension Study to Evaluate Safety and Efficacy of BMN 111 in Children With Achondroplasia

State
Under way
Phase
Phase 2
People
73 taking part
Started
12 Jun 2019
Primary completion
May 2038
Arms
Active BMN 111
Results
None posted
  1. 12 Jun 2019: Trial started
  2. 18 Jun 2019: Trial registered

NCT04554940: A Clinical Trial to Evaluate Safety of Vosoritide in At-risk Infants With Achondroplasia

State
Under way
Phase
Phase 2
People
20 taking part
Started
10 Oct 2020
Primary completion
Dec 2027
Arms
Vosoritide + Standard of Care
Results
None posted
  1. 18 Sep 2020: Trial registered
  2. 10 Oct 2020: Trial started

How the status changed

  1. 19 Nov 2026: First set: Phase 3 trial

About the treatment

Also known as Active BMN 111: Subcutaneous injection of recommended dose of BMN 111 based on weight-band dosing once daily., BMN 111, Voxzogo.

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.